# Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

> **NCT00983346** · PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 17 (actual)

## Conditions studied

- Cancer
- Myeloma
- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00983346
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Lab Staff that was required left the institution, therefore accrual closed prematurely
- **Last updated:** 2016-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983346, "Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00983346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*